Leptomeningeal metastasis—the invasion of the brain and spinal cord’s protective membranes by cancer cells—remains one of the most formidable complications of advanced malignant diseases. This clinical condition, characterized by diffuse dissemination of tumor cells within the cerebrospinal fluid, precipitates rapid neurological decline. Conventional treatments, predominantly radiotherapy and systemic chemotherapy, have shown limited efficacy, with survival rarely extending beyond months. The challenge multiplies when tumor cells acquire resistance to EGFR-TKIs, rendering traditional targeted therapies ineffective.

Furmonertinib, a third-generation EGFR-TKI, has distinguished itself by targeting mutant EGFR variants with increased potency and selectivity, while sparing wild-type receptors, thus minimizing off-target toxicity. This molecule has demonstrated formidable blood-brain barrier penetration—a critical factor for central nervous system (CNS) malignancies and metastases. However, resistance mechanisms inevitably evolve, diminishing the monotherapeutic impact of this agent. Addressing this concern, the integration of bevacizumab, which antagonizes vascular endothelial growth factor (VEGF), disrupting tumor angiogenesis, promises a synergistic attack on tumor biology by simultaneously inhibiting proliferative signaling and vascular nourishment.

The study meticulously tracked molecular alterations in CSF ctDNA, a liquid biopsy surrogate of tumor burden and molecular landscape within the CNS. ctDNA analysis offers unprecedented noninvasive insight into tumor dynamics, enabling real-time assessment of therapeutic efficacy at a molecular resolution. The researchers demonstrated that the addition of bevacizumab potentiated furmonertinib’s effectiveness, as evidenced by significant molecular response rates in the CSF ctDNA, characterized by reduction or clearance of mutant EGFR alleles.

This molecular response corresponded with meaningful improvements in median overall survival and progression-free survival metrics. These outcomes not only corroborate the clinical benefit but also validate the approach of combinational targeted therapy guided by precise molecular monitoring. The integration of ctDNA analysis advances the paradigm of adaptive treatment modulation, wherein therapeutic decisions are continually refined according to evolving tumor genomics rather than solely relying on radiographic or symptomatic changes.

The implications of these findings extend beyond immediate survival benefits. They suggest a route to circumvent established resistance mechanisms such as T790M mutations or alternative pathway activations that frequently undermine EGFR-TKI monotherapies. By interrupting angiogenic support alongside mutant EGFR signaling, the cancer microenvironment becomes less hospitable for resistant clones, potentially delaying or preventing the emergence of treatment refractoriness.

Clinically, this study redefines the management algorithm for patients afflicted by EGFR-mutant leptomeningeal metastases resistant to frontline TKIs. The intervention combines molecular precision with biologic rationale, offering an evidence-based pathway to enhance CNS disease control. Treatment protocols incorporating furmonertinib and bevacizumab could soon become standard of care, pending validation in larger, multi-center trials. For oncologists, neuro-oncologists, and molecular pathologists, these insights underscore the necessity of integrating molecular diagnostics with therapeutic selection.

Moreover, this research highlights the transformative power of CSF ctDNA as a biomarker platform. Beyond diagnostic utility, serial CSF ctDNA evaluations enable clinicians to detect molecular relapse before clinical deterioration and adjust regimens proactively. In an era where personalized medicine thrives, this represents a quantum leap toward truly dynamic, patient-tailored oncology care.

The study also opens avenues for exploring other combinational regimens targeting parallel resistance pathways—immune checkpoint inhibitors, alternative angiogenesis inhibitors, or novel small molecules—in synergy with furmonertinib. The layered molecular approach may be the key to sustained remissions in leptomeningeal metastasis, a realm long constrained by therapeutic nihilism.

While promising, this combinational therapy requires vigilant evaluation of potential adverse effects, including hypertension, proteinuria from bevacizumab, and off-target toxicities from intensive EGFR inhibition. The balance of risks versus benefits necessitates robust clinical monitoring frameworks and patient selection criteria. Future research should elucidate biomarkers predictive of both therapeutic success and toxicity to optimize individual outcomes.

Equally transformative is the study’s methodology which utilized next-generation sequencing platforms to quantify and characterize ctDNA mutations with high sensitivity and specificity. This technological precision allows discrimination between subclonal variants contributing to resistance, facilitating preemptive treatment adjustments. Such advances in molecular diagnostics are pivotal for managing the heterogeneous and rapidly evolving landscape of metastatic CNS cancers.

This pioneering research by Wang and colleagues situates itself at the intersection of molecular oncology, neuro-oncology, and targeted therapeutics, embodying a multidisciplinary approach essential for tackling leptomeningeal metastases. By leveraging novel agents and cutting-edge diagnostics, the clinical community edges closer to converting a once universally fatal complication into a manageable, chronic condition.

As the global oncology field embraces these innovations, patients burdened by leptomeningeal metastasis might anticipate new standards of care that not only extend survival but also preserve neurological function and quality of life. This progress underscores the enduring value of translational research bridging laboratory findings to clinical applications.

In sum, the combinational regimen of furmonertinib plus bevacizumab established by this study offers a potent and promising therapeutic avenue to overcome EGFR-TKI resistance in leptomeningeal metastasis. The intricate molecular insights gained through CSF ctDNA analysis provide an exemplar for personalized treatment strategies targeting intracranial tumor genotypes. These advancements collectively push the frontier toward precision neuro-oncology in the battle against metastatic brain disease.

Subject of Research: Treatment strategies for EGFR-TKI-resistant leptomeningeal metastasis using furmonertinib and bevacizumab, with CSF ctDNA analysis

Article Title: Furmonertinib combined with bevacizumab in EGFR-TKI-resistant leptomeningeal metastasis: analysis of the CSF ctDNA molecular response and survival outcomes

Article References:
Wang, X., Xie, Y., Hu, J. et al. Furmonertinib combined with bevacizumab in EGFR-TKI-resistant leptomeningeal metastasis: analysis of the CSF ctDNA molecular response and survival outcomes. Br J Cancer (2026). https://doi.org/10.1038/s41416-026-03407-z

Image Credits: AI Generated

DOI: 06 April 2026

Lung adenocarcinoma remains the most prevalent histological subtype of non-small cell lung cancer (NSCLC), and the identification of molecular drivers such as mutations in the epidermal growth factor receptor (EGFR) gene has revolutionized therapeutic approaches. While classical EGFR mutations have a high sensitivity to first- and second-generation EGFR TKIs, exon 20 insertions pose a formidable challenge due to steric hindrance and altered ATP-binding site conformations, culminating in intrinsic resistance to many approved targeted agents. This resistance results in limited clinical responses and shorter survival outcomes, underscoring an urgent need for novel, effective therapeutics targeting ex20ins.

The study in question examined 3,571 LUAD patients subjected to next-generation sequencing (NGS) at Henan Cancer Hospital over a three-year period, between January 2020 and December 2022. Within this cohort, EGFR mutations were identified in 45.7% of patients, consistent with prior epidemiological data reflective of the Chinese population. Importantly, 2.44% of these mutations were exon 20 insertions, highlighting a relatively rare but clinically significant subgroup. This frequency aligns with global incidence estimates but underscores the scarcity of robust data focused solely on ex20ins-positive patients in real-world clinical settings.

Furmonertinib, a third-generation EGFR TKI designed to overcome T790M resistance mutations, exhibits a chemical structure engineered to selectively and irreversibly inhibit mutant EGFR while sparing wild-type receptors—a feature that enhances tolerability and efficacy. Previous phase 2 and 3 studies, such as the FAVOUR trial, suggested that high-dose furmonertinib could achieve meaningful tumor control in patients with EGFR ex20ins mutations. However, real-world evidence—critical for understanding drug performance outside controlled clinical trials—remained limited, prompting this investigative effort.

The study focused specifically on 21 patients harboring EGFR ex20ins mutations who received furmonertinib at an escalated dose of 240 mg per day, double the standard dose typically prescribed for classical EGFR mutations. These patients were observed longitudinally, with follow-up data available up to March 2024. Interestingly, a majority of these individuals had undergone prior treatments, including targeted therapies, highlighting a heavily pretreated population often encountered in clinical practice. Despite this, furmonertinib demonstrated promising efficacy endpoints.

Objective response rate (ORR), a vital metric gauging the proportion of patients achieving significant tumor shrinkage, reached an impressive 52.4%. Even more striking was the disease control rate (DCR), which encompasses response plus stable disease, achieving a full 100%. Median progression-free survival (PFS) clocked in at 6.15 months, a noteworthy duration given the refractory nature of ex20ins mutants. Time to treatment failure (TTF), reflecting the interval until therapy cessation for any reason, spanned 10.78 months, while median overall survival (OS) extended to 21.67 months—a remarkable figure indicative of sustained clinical benefit.

Patterns of progression unveiled critical insights into the biological behavior of ex20ins tumors under furmonertinib treatment. Among the 18 patients who experienced progression, central nervous system (CNS) involvement was predominant, with neurological progression documented in 11 cases. Thoracic and hepatic metastases were less frequent but still clinically relevant. This pattern suggests that, despite systemic disease control, CNS penetration remains a key consideration for therapeutic optimization, echoing the known challenges posed by the blood-brain barrier in lung cancer management.

Safety and tolerability are paramount in chronic cancer therapies, and furmonertinib’s profile was favorable in this regard. The most frequently reported adverse event was diarrhea, a manageable side effect commonly associated with EGFR TKIs. Notably, no patients discontinued treatment due to toxicity, highlighting the drug’s acceptable safety margin even at high doses. This tolerability is crucial for maintaining quality of life and adherence during prolonged treatment courses.

The implications of these findings extend beyond mere clinical outcomes. The study reinforces the significant heterogeneity among EGFR mutations and advocates for mutation-specific approaches in lung adenocarcinoma treatment. High-dose furmonertinib emerges as a potent contender in the armamentarium against ex20ins mutations, bridging a previously unmet need and potentially improving survival trajectories in this difficult-to-treat subgroup.

Furthermore, this research underscores the value of integrating comprehensive genomic profiling via NGS into routine clinical workflows. Early and precise identification of rare mutations like ex20ins facilitates tailored therapeutic strategies, ensuring patients receive the most effective treatment available. The study also highlights the utility of real-world data in complementing randomized clinical trials, capturing heterogeneous patient populations often excluded from stringent protocols.

Mechanistically, furmonertinib’s covalent binding to mutant EGFR domains and enhanced blood-brain barrier permeability may underlie its clinical efficacy and CNS activity, areas that warrant further biochemical and pharmacokinetic exploration. Future studies should delve deeper into resistance mechanisms emerging post-treatment and explore combinatorial regimens including CNS-directed therapies to address neurological progression.

In conclusion, this real-world investigation presents robust evidence supporting high-dose furmonertinib’s efficacy and manageable safety profile in patients with LUAD harboring EGFR exon 20 insertions. As the oncology community strives for precision medicine, such data are instrumental in informing clinical decision-making and guiding drug development. With ongoing advancements, patients with this historically challenging mutation spectrum may soon experience improved outcomes and renewed hope.

Subject of Research: Lung adenocarcinoma patients with EGFR exon 20 insertion mutations treated with high-dose furmonertinib.

Article Title: EGFR exon 20 insertions mutation in lung adenocarcinoma and its response by high-dose of Furmonertinib: a real-world study.

Article References: Yang, S., Liu, Y., Zhao, J. et al. EGFR exon 20 insertions mutation in lung adenocarcinoma and its response by high-dose of Furmonertinib: a real-world study. BMC Cancer 25, 900 (2025). https://doi.org/10.1186/s12885-025-14313-7

Image Credits: Scienmag.com

DOI: https://doi.org/10.1186/s12885-025-14313-7

Keywords: Lung adenocarcinoma, EGFR exon 20 insertion, furmonertinib, targeted therapy, tyrosine kinase inhibitor, real-world study, progression-free survival, overall survival, CNS progression, EGFR mutations

Over the past decade, third-generation EGFR tyrosine kinase inhibitors (TKIs) like osimertinib have revolutionized the treatment landscape for NSCLC, particularly for patients exhibiting EGFR mutations. Despite dramatic improvements in clinical outcomes, the inevitable emergence of drug resistance remains a formidable challenge, often mediated by secondary genetic alterations such as MET amplification. This amplification leads to compensatory bypass signaling, rendering EGFR-targeted therapies less effective and limiting long-term patient survival.

The innovative research team adopted an in silico drug repurposing tool known as DRAR-CPI (Drug Repositioning Approach based on the Chemical-Protein Interactome), which leverages chemical-protein interactome analysis to systematically probe existing drugs for their potential to interfere with oncogenic proteins. By analyzing a comprehensive profile of known MET inhibitors, the team computationally screened for candidate molecules that could suppress MET activity, ultimately pinpointing fexofenadine as a unexpected but highly promising MET inhibitor candidate.

Fexofenadine, widely prescribed globally for allergic rhinitis and chronic urticaria, has an established clinical safety profile and well-characterized pharmacodynamics, making it an attractive candidate for repositioning in oncology. To validate the computational predictions, the researchers conducted a series of biochemical and cellular assays. Fexofenadine was confirmed to inhibit recombinant MET kinase activity in cell-free systems, demonstrating direct target engagement. Furthermore, in osimertinib-resistant NSCLC cell lines with MET amplification, fexofenadine significantly reduced phosphorylation of MET and downstream signaling molecules, indicating disruption of oncogenic signaling pathways responsible for therapeutic resistance.

The study extended its molecular characterization through kinome-wide profiling (KINOME scan), revealing that fexofenadine’s kinase inhibition spectrum closely resembled that of cabozantinib, an FDA-approved MET inhibitor with known anticancer efficacy. This similarity underscores the potential of fexofenadine to mimic MET-targeted pharmacological effects, albeit with an established safety and dosing paradigm derived from its long-term use in allergy treatment.

Crucially, the combinatorial treatment of fexofenadine with osimertinib in MET-amplified and EGFR T790M-mutated NSCLC cellular models produced a pronounced synergistic anticancer effect. This combination effectively restored drug sensitivity and inhibited cellular proliferation more robustly than either agent alone. Transcriptomic analyses of cancer cells following fexofenadine treatment revealed significant modulation of gene expression profiles enriched in metastasis-related biological pathways, suggesting that fexofenadine might impact tumor progression and metastatic potential beyond merely overcoming resistance.

To bridge laboratory findings with potential clinical utility, the research leveraged patient-derived tumor xenograft (PDX) models—a gold standard in cancer research for recapitulating the molecular heterogeneity and biological complexity of human tumors. Remarkably, mice implanted with osimertinib-resistant NSCLC PDX tumors exhibited significant tumor regression upon combined fexofenadine and osimertinib treatment compared to control or single-agent groups. Importantly, this antitumor effect was achieved without inducing notable toxicity or adverse effects in the animal models, highlighting the safety of the repurposed drug combination.

The implications of this study are profound, as it demonstrates the feasibility of repurposing a common antihistamine to target a pivotal resistance pathway in cancer therapy. By circumventing the costly and time-consuming traditional drug development pipeline, this approach expedites the translation of existing medications to address unmet clinical needs in oncology. Moreover, it underscores the power of integrating computational biology and chemical-protein interactome analyses to uncover hidden therapeutic potentials within the pharmacopeia.

Beyond the immediate impact on NSCLC treatment paradigms, these findings illuminate a broader principle: that drug resistance in cancer can be tactically reversed by rational drug repositioning guided by molecular interactome insights. This methodology could be generalized across various cancer types exhibiting resistance through distinct molecular mechanisms, heralding a new era of precision oncology therapeutics optimized through data-driven repurposing strategies.

Future clinical trials are warranted to evaluate the efficacy and safety of fexofenadine as an adjuvant to osimertinib in NSCLC patients exhibiting MET amplification-driven resistance. If successful, this could transform standard care protocols and greatly enhance patient outcomes by integrating an affordable, accessible drug into complex cancer regimens. Furthermore, comprehensive biomarker analyses may identify subpopulations most likely to benefit from this combination, facilitating personalized medicine approaches that are both effective and economically sustainable.

In summary, the pioneering work by Prof. Kenneth To, Dr. William Cho, and their collaborators underscores an exciting intersection of computational drug discovery, molecular oncology, and clinical pharmacology. By unveiling fexofenadine’s unexpected role as a MET inhibitor capable of overcoming osimertinib resistance, this research paves the way for innovative therapeutic combinations poised to extend survival and improve quality of life for lung cancer patients worldwide.

—

Subject of Research: Overcoming osimertinib resistance in non-small cell lung cancer through drug repurposing of fexofenadine as a MET inhibitor.

Article Title: Fexofenadine Overcomes Osimertinib Resistance by Inhibiting c‐Met in Non‐Small Cell Lung Cancer

News Publication Date: 14-Apr-2025

Web References: http://dx.doi.org/10.1002/mog2.70019

Image Credits: Kenneth To